| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2603512 | Toxicology in Vitro | 2008 | 4 Pages |
Abstract
Titanocene dichloride and two of its derivatives (Titanocene Y and C) were tested on human umbilical vein endothelial cells (HUVEC) sprouting in a spheroid-based cellular angiogenesis assay in order to determine IC50 values of inhibition. Titanocene dichloride and Titanocene Y inhibited HUVEC sprouting in this angiogenesis assay with IC50 values of 19 μM and 4.9 μM, while Titanocene C surprisingly showed no inhibition. This classifies Titanocene dichloride as a purely anti-angiogenic anticancer drug and Titanocene C as a purely cytotoxic anticancer drug. On the other hand, Titanocene Y combines both favourable anticancer activities and seems to be the drug candidate of choice for further optimisation.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Holger Weber, James Claffey, Megan Hogan, Clara Pampillón, Matthias Tacke,